Inflammatory ocular events after inactivated COVID-19 vaccination

Figures & data

Table 1. Demographic and clinical characteristics of patients having ocular adverse events following COVID-19 vaccination.

PatientNo	Gender	Age (years)	Laterality	Diagnosis	VaccineReceived	Doses	Days AfterVaccination	PositiveSerologicTest	TreatmentReceived	Presenting BCVA	Final BCVA	Outcome
1	F	36	OS	Anterior uveitis	Corona Vac	1	3		Topical steroidoral steroid	20/100	20/25	1 mild recurrent episode and resolved
2	F	32	OD	Anterior uveitis	Corona Vac	2	30		Topical steroid	20/30	20/20	Resolved
3	F	31	OU	Anterior uveitis	1. Corona Vac2. BBIBP-CorV	2	7	HLAB27(+)	Topical steroid	20/20, 20/20	20/20, 20/20	Resolved
4	M	59	OS	Herpetic keratitisiridocyclitis	BBIBP-CorV	2	12		Topical steroidanti-viral treatment	20/30	20/25	Resolved
5	F	28	OU	Posterior uveitis	Corona Vac	1	14		IVT dexamethasone	20/30, 20/40	20/20, 20/20	Resolved

COVID-19 vaccination = coronavirus disease 2019, BCVA = best-corrected visual acuity, M = male, F = Female, OD = right eye, OS = left eye, OU = both eye, HLA-B27 = human leukocyte antigen B27, IVT = intravitreal injection.

Figure 1. Patient 1 was diagnosed as anterior uveitis of left eye. She received both topical and a fast systemic tapering dose of glucocorticoids due to the severe symptom. (a) Showed normal anterior segment of right eye. (b) Showed anterior inflammation and irregular pupil of left eye.

Figure 2. Patient 5 was diagnosed as bilateral posterior uveitis resembling Harada disease 14 days after first dose of inactivated COVID vaccine. (a and b) Fundus photos of right and left eye at the first presentation, which showed serous retinal detachment in both eyes. The left eye was more severe than the right eye. (c and d) optical coherence tomography (OCT) of right and left eye. Macula was involved in the left eye. Intravitreal dexamethasone implantations were performed and the bilateral episode completely resolved without recurrence. (e and f) Fundus photos after treatment. (g and h) OCT of right eye and left eye respectively after treatment.